PMID- 34327063
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 2167-8359 (Print)
IS  - 2167-8359 (Electronic)
IS  - 2167-8359 (Linking)
VI  - 9
DP  - 2021
TI  - Clinical and prognostic relevance of CXCL12 expression in acute myeloid leukemia.
PG  - e11820
LID - 10.7717/peerj.11820 [doi]
LID - e11820
AB  - BACKGROUND: Accumulating studies have been made to understand the association 
      between CXC chemokine ligand-12 (CXCL12)/CXC chemokine receptor 4 (CXCR4) and 
      acute myeloid leukemia (AML). However, large-scale data analysis of potential 
      relationship between CXCL12 and AML remains insufficient. METHODS: We collected 
      abundant CXCL12 expression data and AML samples from several publicly available 
      datasets. The CIBERSORT algorithm was used to quantify immune cell fractions and 
      the online website of STRING was utilized for gene ontology (GO) enrichment and 
      Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. The statistical analysis 
      and graphical work were mainly performed via the R software. RESULTS: CXCL12 
      expression was extremely down-regulated in AML. Clinically, low CXCL12 expression 
      was correlated with higher white blood cells (WBCs) (P < 0.0001), more blasts in 
      bone marrow (BM) (P < 0.001) and peripheral blood (PB) (P < 0.0001), 
      FLT3-internal tandem duplications (FLT3-ITD) (P = 0.010) and NPM1 mutations (P = 
      0.015). More importantly, reduced CXCL12 expression predicted worse overall 
      survival (OS) and event-free survival (EFS) in all AML, non-M3-AML, and 
      cytogenetically normal (CN)-AML patients in three independent cohorts. As for 
      immune cell infiltration, high CXCL12 expressed groups tended to harbor more 
      memory B cells and plasma cells infiltration while low CXCL12 expressed groups 
      exhibited more eosinophils infiltration. GO enrichment and KEGG pathways analysis 
      revealed the potential biological progress the gene participating in. 
      CONCLUSIONS: CXCL12 is significantly down-regulated in AML and low CXCL12 
      expression is an independent and poor predictor of AML prognosis. CXCL12 
      expression level correlates with clinical and immune characteristics of AML, 
      which could provide potential assistance for treatment. Prospective studies are 
      needed to further validate the impact of CXCL12 expression before routine 
      clinical application in AML.
CI  - (c) 2021 Wang et al.
FAU - Wang, Shi-Sen
AU  - Wang SS
AD  - Department of Hematology, Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu, China.
FAU - Xu, Zi-Jun
AU  - Xu ZJ
AD  - Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, 
      Jiangsu, China.
AD  - Zhenjiang Clinical Research Center of Hematology, Zhenjiang, Jiangsu, China.
FAU - Jin, Ye
AU  - Jin Y
AD  - Department of Hematology, Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu, China.
AD  - Zhenjiang Clinical Research Center of Hematology, Zhenjiang, Jiangsu, China.
FAU - Ma, Ji-Chun
AU  - Ma JC
AD  - Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, 
      Jiangsu, China.
AD  - Zhenjiang Clinical Research Center of Hematology, Zhenjiang, Jiangsu, China.
FAU - Xia, Pei-Hui
AU  - Xia PH
AD  - Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, 
      Jiangsu, China.
AD  - Zhenjiang Clinical Research Center of Hematology, Zhenjiang, Jiangsu, China.
FAU - Wen, Xiangmei
AU  - Wen X
AD  - Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, 
      Jiangsu, China.
AD  - Zhenjiang Clinical Research Center of Hematology, Zhenjiang, Jiangsu, China.
FAU - Mao, Zhen-Wei
AU  - Mao ZW
AD  - Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, 
      Jiangsu, China.
FAU - Lin, Jiang
AU  - Lin J
AD  - Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, 
      Jiangsu, China.
AD  - Zhenjiang Clinical Research Center of Hematology, Zhenjiang, Jiangsu, China.
FAU - Qian, Jun
AU  - Qian J
AD  - Department of Hematology, Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, Jiangsu, China.
AD  - Zhenjiang Clinical Research Center of Hematology, Zhenjiang, Jiangsu, China.
LA  - eng
PT  - Journal Article
DEP - 20210720
PL  - United States
TA  - PeerJ
JT  - PeerJ
JID - 101603425
PMC - PMC8300536
OTO - NOTNLM
OT  - AML
OT  - CXCL12
OT  - CXCR4
OT  - Gene expression
OT  - Prognosis
OT  - SDF-1
COIS- The authors declare that they have no competing interests.
EDAT- 2021/07/31 06:00
MHDA- 2021/07/31 06:01
PMCR- 2021/07/20
CRDT- 2021/07/30 06:47
PHST- 2021/03/31 00:00 [received]
PHST- 2021/06/29 00:00 [accepted]
PHST- 2021/07/30 06:47 [entrez]
PHST- 2021/07/31 06:00 [pubmed]
PHST- 2021/07/31 06:01 [medline]
PHST- 2021/07/20 00:00 [pmc-release]
AID - 11820 [pii]
AID - 10.7717/peerj.11820 [doi]
PST - epublish
SO  - PeerJ. 2021 Jul 20;9:e11820. doi: 10.7717/peerj.11820. eCollection 2021.